Legal News

Life Sciences weekly highlights—29 March 2018

Published on: 29 March 2018

Table of contents

  • Manufacture, marketing and sale
  • General Court annuls EMA decision refusing to validate application for orphan designation (Shire Pharmaceuticals Ireland Ltd v EMA)
  • Innovate UK to invest £10m in antimicrobial resistance projects
  • Brexit
  • MLex Special Report: Rival Visions of a Brexit Deal
  • Brexit—European Council adopts guidelines on future EU-UK relationship
  • EU Commission sets out position on IP rights post-Brexit
  • Disputes and regulatory enforcement
  • Ombudsman finds European Medicines Agency refusal to identify company was ‘maladministration’
  • IP
  • More sections of this document available when you sign-in to Lexis+ or register for a free trial.

Article summary

This week’s edition of Life Sciences highlights includes details of the General Court case Shire Pharmaceuticals Ireland Ltd v EMA concerning an application for orphan designation, news of The European Ombudsman’s decision that EMA’s refusal to identify a company that asked for public access to a report on a drug constituted maladministration, and the latest updates on Brexit, including the position on IP rights in the latest iteration of the draft withdrawal agreement.

Popular documents